ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor and Ureka

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today provided a progress update on activities around Covid-19.

On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’ programs, one of which was in ‘Antivirals’. Investigation of the application of the Ureka peptide technologies within this Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies. Further exploratory work continues on this program.

As part of an overall evaluation of how we might apply our patented technologies to the fight against the Covid-19 epidemic, within our ‘Autoimmunity’ therapy  area, we have also been considering the unique way that Lupuzor™ interacts with the immune system and any potential application to Covid-19.

In this respect we note the results* of a recent study conducted at Emory University Atlanta GA,  suggesting that Covid-19 (SARS-COV-2) patients and systemic lupus erythematosus (SLE) patients experiencing flares might share similar inflammatory symptoms, underpinned by similar mechanisms (role of cytokines). Lupuzor™ is a modulator of the immune response and an anti-inflammatory agent, which has activity against SLE (lupus), an autoimmune disease, as well as against other inflammatory diseases. ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing  Lupuzor™ into a new optimised international Phase III trial this year in lupus patients.

*“Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extraordinary B cell activation” -https://doi.org/10.1101/2020.04.29.20083717.

Given the findings of the Atlanta research group, we postulate that Lupuzor™ may help to reduce or perhaps prevent the occurrence of the cytokine storm seen in Covid-19 patients. Further exploratory work is ongoing to assess Lupuzor’s™ possible potential and clinical program in Covid-19 patients.

Commenting on the announcement, Dimitri Dimitriou, CEO and Dr Robert Zimmer, President & CSO of ImmuPharma said: “As the Covid-19 pandemic has unfolded, ImmuPharma has been evaluating how it can best contribute its expertise and resources to help in the global response. Using our longstanding knowledge of peptide based technology, provides us with a number of opportunities, to help bring together a therapy that could be effective against the inflammation that causes the serious complications of Covid-19. We look forward to providing further updates when appropriate”.   

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Pregnancy outcomes greatly improved in lupus patients

    Historically, pregnancy in patients with systemic lupus erythematosus (SLE) was considered so risky that physicians counseled women to avoid becoming pregnant and recommended that women carrying a child terminate their pregnancy. Now, a new study published

    Immupharma Plc

    Immupharma PLC Subscription to raise £2.66 million

    Commenting, ImmuPharma’s Chairman, Tim McCarthy, said: “We are delighted to be welcoming back Lanstead as a significant shareholder of the Company. Lanstead has been very supportive of the Company since their first investment in 2016 and

    Immupharma Plc

    10 Surprising Autoimmune Disease Facts You Need to Know

    If it seems like everyone and her grandma knows someone with an autoimmune disease, that’s because the term is a giant bucket that holds some 80 conditions, some as well-known as multiple sclerosis or type 1 diabetes, and as

    Immupharma Plc

    Autoimmune Diseases That Are Different For Women Than Men

    Research is just starting to explore how different conditions affect female-bodied people differently to male-bodied people. One of these areas in particular is in autoimmune conditions, where the immune system treats healthy tissues and cells as

    Immupharma Plc

    Why Autoimmune Diseases Cause the Body to Attack Itself

    A new study published in the journal Cell explores the cellular “runaway train” that allows lupus and other autoimmune diseases to spread throughout the body. Autoimmune disease is exactly what it sounds like—the body mistakenly fighting

    Immupharma Plc

    Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM)

    ImmuPharma’s Tim McCarthy discusses their final results, spend going forward, corporate strategy for Lupuzor, Nucant & Ureka, key milestones for shareholders and the initiation note issued by The Life Sciences Division in this exclusive interview with DirectorsTalk

    Immupharma Plc

    World Lupus Day: new report reveals need for care improvements

    The initiative is in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community. The report urges that we need increased awareness of lupus amongst